



Press release – Paris, September 13, 2023

Danone reinforces European medical nutrition manufacturing footprint with €50 million line expansion in Poland

Danone today announces a €50 million line expansion of its Opole, Poland, production facility, to expand its medical nutrition capabilities to serve patients across the world, as it targets further growth in the adult medical nutrition market.

The expansion comes as macro trends point to a growing demand for the category as populations continue to age and the rate of chronic diseases increases. Many people will require medical nutrition at some stage of their lives, with diseases such as cancer and strokes resulting in malnutrition of patients. Although medical nutrition is proven to support patient outcomes, only one in three patients who could benefit from it currently receive it – showing that there is a growing need for medical nutrition solutions.

Specialized nutrition (which includes medical nutrition) accounts for 30% of Danone's total revenues, with a growth of +10% like-for-like in 2022. This investment marks further progress against the Renew Danone strategy to drive growth within its categories, and notably in its medical nutrition activities where Danone aims at serving a growing number of patients.

Danone is already the market leader across Europe in adult medical nutrition. The Opole investment will allow Danone to expand its highly specialized production capabilities through a new medical nutrition production line which will serve patients who are dependent on feeding tubes as they cannot swallow or drink normally. Opole will be Danone's second European plant to produce Danone's enteral nutrition range Nutrison.

Antoine de Saint-Affrique, Danone CEO, said: *"Our long-standing patient-centric approach is at the heart of our specialized nutrition strategy. The line expansion we're making into the Opole plant will accelerate our innovation within adult medical nutrition, expanding on our 100 years of expertise in the medical nutrition field. The investment will result in more agility in our supply chain, via our existing factories, meaning we can serve more patients, better, locally, while also delivering on our mission to bring health through food to as many people as possible. This expansion is the latest example of our Renew Danone strategy in action, as we invest to get ahead of evolving health needs and develop our adult nutrition activities."*

The Opole production plant is a state-of-the-art factory, awarded by the World Economic Forum for its digital transformation, and is one of the largest Danone factories in Europe, occupying a total area of almost 13 ha and employing 700 people. It currently manufactures baby formula and baby food products Bebilon, Bebiko and Bobovita. The new line will cover 7,000 m² of additional space.

- Ends -

Notes to editors:

What is medical nutrition?

Medical nutrition is an effective way to help address nutritional insufficiencies when patients are unable to meet their daily nutritional requirements with normal foods.

Used under medical supervision, medical nutrition is often a key part of treatment besides medication, surgery and/or diet and lifestyle. Medical nutrition can be either a short term or long-term solution, related to individual nutritional needs.

About Danone (www.danone.com):

Danone is a leading global food and beverage company operating in three health focused, fast-growing and on-trend categories: Essential Dairy & Plant-Based products, Waters and Specialized Nutrition. With a long-standing mission of bringing health through food to as many people as possible, Danone aims to inspire healthier and more sustainable eating and drinking practices while committing to achieve measurable nutritional, social, societal and environment impact. Danone has defined its Renew strategy to restore growth, competitiveness, and value creation for the long-term. With 100,000 employees, and products sold in over 120 markets, Danone generated €27.7 billion in sales in 2022. Danone's portfolio includes leading international brands (Actimel, Activia, Alpro, Aptamil, Danette, Danio, Danonino, evian, Nutricia, Nutrilon, Volvic, among others) as well as strong local and regional brands (including Aqua, Blédina, Bonafont, Cow & Gate, Mizone, Oikos and Silk). Listed on Euronext Paris and present on the OTCQX market via an ADR (American Depositary Receipt) program, Danone is a component stock of leading sustainability indexes including the ones managed by Moody's and Sustainalytics, as well as the Ethibel Sustainability Index, the MSCI ESG Indexes, the FTSE4Good Index Series, Bloomberg Gender Equality Index, and the Access to Nutrition Index. Danone's ambition is to be B-Corp certified at global level in 2025.